Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand.
Tanawan KongmalaiJuthamas PrawjaengPhorntida HadnorntunPattara LeelahavarongUsa ChaikledkaewAmmarin ThakkinstianVaralak SrinonprasertPublished in: PharmacoEconomics - open (2024)
Adding SGLT2i to standard treatment reduced HF hospitalization and mortality rates and improved QALYs in T2D-HF patients. Nevertheless, they would not be cost-effective at current prices in Thailand.
Keyphrases
- glycemic control
- type diabetes
- weight loss
- end stage renal disease
- newly diagnosed
- cardiovascular disease
- ejection fraction
- chronic kidney disease
- quality improvement
- heart failure
- cardiovascular events
- emergency department
- metabolic syndrome
- combination therapy
- prognostic factors
- adipose tissue
- skeletal muscle
- adverse drug
- replacement therapy